CAMBRIDGE, Mass., Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Spero Therapeutics, Inc. ( Nasdaq: SPRO ) , a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant ( MDR ) bacterial infections, today announced that on ...

SPRO

<p>马萨诸塞州剑桥，2025 年 11 月 28 日（GLOBE NEWSWIRE）-- Spero Therapeutics, Inc.（纳斯达克：SPRO），一家专注于识别和开发罕见疾病及多重耐药（MDR）细菌感染新疗法的临床阶段生物制药公司，今天宣布</p>

Spero Therapeutics 宣布根据纳斯达克上市规则 5635(c)(4) 授予诱导性股票期权